MeesPierson

Anagenex Strengthens Board of Directors with Appointments of Robert Forrester and Isaac Ro

Retrieved on: 
星期四, 十一月 16, 2023
Research, Technology, Other Health, General Health, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Other Science, WGS, Verastem Oncology, Patient, Middlebury College, GeneDx, Partner, Goldman Sachs, University of Bristol, Exact sciences, Quest Diagnostics, SVB Securities, Drug discovery, History, MeesPierson, LP, LL.B, Pharmaceutical industry, Pfizer

The company also welcomed Isaac Ro to its Board of Directors.

Key Points: 
  • The company also welcomed Isaac Ro to its Board of Directors.
  • “Robert and Isaac’s extensive experience as life science executives is invaluable to the Anagenex team as we realize our vision of becoming a vertically integrated small molecule drug discovery company,” said Nicolas Tilmans, CEO of Anagenex.
  • “Our unique AI driven platform has already powered two lead programs with novel chemical matter and continues to scale.
  • Isaac Ro has extensive experience as an investor, board member and operator having navigated multiple financings, M&A transactions and exits.

OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

Retrieved on: 
星期三, 一月 4, 2023
Pillar, GKOS, CDH6, CFO, Patient, NYSE, Hope, General partnership, NTLA, Verastem Oncology, University of Bristol, LP, Growth, UBS, ADC, MeesPierson, Equal Credit Opportunity Act, Retirement, FDA, BLU, Yale University, Therapy, LL.B, Investment, Barclays, Cancer, Senior advisor, WuXi Biologics, Pharmaceutical industry, Pfizer

NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors.

Key Points: 
  • NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors.
  • "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board.
  • Mr. Forrester has more than 25 years of life sciences experience and has held leadership roles in private and public pharmaceutical companies.
  • OnCusp Therapeutics is a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics.

DGAP-News: MPC Capital's subsidiary Cairn Real Estate completes EUR 120 million capital increase for Gateway Fund

Retrieved on: 
星期一, 十一月 16, 2020
ABN AMRO, Real estate investment trust, MeesPierson, Banks, Financial services, Banking

November 2020 - MPC Capital AG (Deutsche Brse Scale, ISIN DE000A1TNWJ4), through its Dutch subsidiary Cairn Real Estate, has successfully completed a capital increase of EUR 120 million for the "Gateway Fund".

Key Points: 
  • November 2020 - MPC Capital AG (Deutsche Brse Scale, ISIN DE000A1TNWJ4), through its Dutch subsidiary Cairn Real Estate, has successfully completed a capital increase of EUR 120 million for the "Gateway Fund".
  • Originally launched as "ABN AMRO MeesPierson Real Estate Growth Fund", the fund is an unlisted REIT and focuses on the market for logistics and light industrial real estate in the Netherlands and Germany.
  • In addition to existing investors, who contributed around EUR 20 million in fresh capital to the fund, new institutional investors also participated in the capital increase with around EUR 100 million.
  • Pieter Akkerman, Managing Director of Cairn Real Estate: "Logistics and light industrial properties are stable cornerstones of our real estate strategy.